Results 31 to 40 of about 124,813 (135)
Loss of IGF‐1R impairs DNA‐PKcs recruitment to chromatin leading to defective end‐joining
Molecular Oncology, EarlyView.IGF‐1R promotes radioresistance by facilitating DNA‐PKcs recruitment to chromatin, enabling non‐homologous end‐joining (NHEJ) repair of double‐strand breaks. Inhibition or loss of IGF‐1R disrupts this recruitment to damage sites, driving compensatory reliance on microhomology‐mediated end‐joining (MMEJ) repair.
Matthew O. Ellis +3 more
wiley +1 more source
, 2017 A: Immunoblotting of IGF-1R, pho-IGF-1R and pho-IRS-1 in proliferating BPH-1 cells treated with various doses of metformin for 24 hours, or with 5 mM metformin for the indicated times.
Cyrus Rassoulian (3808834) +6 more
core +1 more source
Advanced Science, EarlyView.AARS1 drives PI3K–AKT–mTOR‐dependent glycolysis in bladder cancer, promoting lactate accumulation, increased lactylation, H3K27la enrichment at the HK2 promoter, and HK2 transcription. HK2 reinforces glycolysis, sustaining a metabolic–epigenetic program associated with tumor progression, recurrence, and metastasis.
Qin Yuan +13 more
wiley +1 more source
IGF-1R protein levels, lung histology and respiratory function in adult IGF-1Rneo/− mice. A
, 2013 , Western immunoblot of IGF-1R in lung from mice with distinct combinations of mutant IGF-1R alleles. Total proteins were extracted from lung tissue from IGF-1Rneo/−, IGF-1R+/−, IGF-1R+/neo and IGF-1R+/+ mice (n = 3 for each genotype), and IGF-1R ...
Annick Clement (4917226) +13 more
core +1 more source
Efficacy, safety and cost‐effectiveness of CAR‐T therapy
British Journal of Clinical Pharmacology, EarlyView.CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher +7 more
wiley +1 more source
, 2021 AimInsulin-like growth factor-1 receptor (IGF-1R) is one of the main members of the tyrosine protein kinase receptor family. This receptor binds insulin-like growth factor-1 (IGF-1) with a high affinity. IGF-1 is a member of a family of proteins involved
Yinqi Zhang (11652286) +10 more
core +1 more source
New insights into epileptic spasm generation and treatment from the TTX animal model
Epilepsia Open, EarlyView.Abstract Currently, we have an incomplete understanding of the mechanisms underlying infantile epileptic spasms syndrome (IESS). However, over the past decade, significant efforts have been made to develop IESS animal models to provide much‐needed mechanistic information for therapy development.
John W. Swann +2 more
wiley +1 more source
, 2018 Loganin, a major iridoid glycoside obtained from fruits of Cornus officinalis, possesses anti‐inflammatory, antitumor, antidiabetic, and osteoporosis prevention effects.
Tseng, Yu‐Ting +3 more
core +1 more source
, 2021 AimInsulin-like growth factor-1 receptor (IGF-1R) is one of the main members of the tyrosine protein kinase receptor family. This receptor binds insulin-like growth factor-1 (IGF-1) with a high affinity. IGF-1 is a member of a family of proteins involved
Yinqi Zhang (11652286) +10 more
core +1 more source
The Prognostic and Clinicopathological Significance of IGF-1R in NSCLC: a Meta-Analysis
Cellular Physiology and Biochemistry, 2017 Background/Aims: Accumulating studies have reported that IGF-1R (Insulin-like growth factor-1 receptor) is aberrantly expressed in NSCLC (non-small cell lung cancer), but the role of IGF-1R in NSCLC remains controversial.
Jun Zhao +5 more
doaj +1 more source